Saturday , November 18 2017
Home / Resources / Videos / ADA 2017 / Todd Hobbs Part 5, The Future of Novo Nordisk

Todd Hobbs Part 5, The Future of Novo Nordisk

In part 5, the conclusion, of this Exclusive Interview, Dr. Todd Hobbs talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California, about what’s in the pipeline for Novo Nordisk and smart insulin.

Dr. Todd Hobbs is Vice President and Chief Medical Officer for Novo Nordisk in North America, where he leads the organization’s focus on the implications of diabetes for the patient, healthcare system, and healthcare professionals. He provides overall medical guidance to Novo Nordisk’s diabetes and obesity-related projects.

Transcript of this video segment:

Steve: Novo has been in the business for a while. They have a lot of different drugs. Maybe you can share with us, what’s in the pipeline that is exciting?

Dr. Hobbs: I think we talked about it which is oral semaglutide. That’s probably the most exciting, our weekly injection is going to be here obviously a lot sooner. Hopefully we will have a ruling at the end of the year. That data is very robust, it really will indicate to most everybody that looks at the data, that it is the best GLP-1 data that has been seen. When you talk about the excitement of being able to reproduce that kind of data and take a once-a-day pill, I think that’s exciting. That’s in the relatively manageable 3- to 5-year timeframe. We are still exploring things like a weekly insulin injection or combining a weekly insulin injection with a weekly GLP-, things like that, but that’s further down the pipeline.

Steve: Are you doing anything with smart insulin?

Dr. Hobbs: We are looking at a liver preferred insulin, there are a lot of ways to look at how you would make a smart insulin. It is still very early, but we know that if we can actually have more effects in the intra-hepatic circulation around the liver and less in the periphery, that should cut down on the risk of hypoglycemia and weight increase so that’s how we are going about it, but again it’s still rather early for that one. If we could have an insulin that would only work to get your glucose down to the appropriate level and then stop working that would be the dream, and we are going to continue looking for that.

Steve: I know you’ve got to go, but I have one favorite question. It has nothing to do with Novo… If you could have any HbA1c level what would that number be on that piece of paper?

Dr. Hobbs: 5%

Return to the main page.